Podcasts about Novartis

Swiss pharmaceutical company

  • 1,328PODCASTS
  • 3,485EPISODES
  • 28mAVG DURATION
  • 1DAILY NEW EPISODE
  • Jun 19, 2025LATEST
Novartis

POPULARITY

20172018201920202021202220232024

Categories



Best podcasts about Novartis

Show all podcasts related to novartis

Latest podcast episodes about Novartis

ASCO Daily News
ASCO25 Recap: CHALLENGE, DESTINY-Breast09, and More

ASCO Daily News

Play Episode Listen Later Jun 19, 2025 25:45


Dr. John Sweetenham and Dr. Erika Hamilton highlight key abstracts that were presented at ASCO25, including advances in breast and pancreatic cancers as well as remarkable data from the use of structured exercise programs in cancer care. Transcript Dr. Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham. Today, we'll be discussing some of the key advances and novel approaches in cancer care that were presented at the 2025 ASCO Annual Meeting. I'm delighted to be joined again by the chair of the Meeting's Scientific Program, Dr. Erika Hamilton. She is a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee.  Our full disclosures are available in the transcript of this episode. Dr. Hamilton, congratulations on a fantastic meeting. From the practice-changing science to the world-renowned speakers at this year's Meeting, ASCO25 really reflected the amazing progress we're seeing in oncology today and the enormous opportunities that lie ahead of us. And thanks for coming back on to the podcast today to discuss some of these advances. Dr. Hamilton: Thanks, Dr. Sweetenham. I'm happy to join you today. It really was an impactful ASCO Annual Meeting. I probably am biased, but some great research was presented this year, and I heard lots of great conversations happening while we were there. Dr. Sweetenham: Yeah, absolutely. There was a lot of buzz, as well as a lot of media buzz around the meeting this year, and I think that's probably a good place to start. So I'd like to dive into abstract number LBA3510. This was the CHALLENGE trial, which created a lot of buzz at the meeting and subsequently in the media. This is the study that was led by the NCI Canada Clinical Trials Group, which was the first randomized phase 3 trial in patients with stage III and high-risk stage II colon cancer, which demonstrated that a post-treatment structured exercise program is both feasible and effective in improving disease-free survival in this patient group. The study was performed over a long period of time and in many respects is quite remarkable. So, I wonder if you could give us your thoughts about this study and whether you think that this means that our futures are going to be full of structured exercise programs for those patients who may benefit. Dr. Hamilton: It's a fantastic question. I think that this abstract did create a lot of buzz. We were very excited when we read it. It was highlighted in one of the Clinical Science Symposium sessions. But briefly, this was a phase 3 randomized trial. It was conducted at 55 centers, so really a broad experience, and patients that had resected colon cancer who completed adjuvant therapy were allowed to participate. There were essentially 2 groups: a structured exercise program, called ‘the exercise group,' or health education materials alone, so that was called just ‘the health education group.' And this was a 3-year intervention, so very high quality. The primary end point, as you mentioned, was disease-free survival. This actually accrued from 2009 to 2024, so quite a lift, and almost 900 patients underwent randomization to the exercise group or the health education group. And at almost 8 years of follow-up, we saw that the disease-free survival was significantly longer in the exercise group than the health education group. This was essentially 80.3% of patients were disease-free in exercise and 73.9% in the health education group. So a difference of over 6 percentage points, which, you know, at least in the breast cancer world, we make decisions about whether to do chemotherapy or not based on these kind of data. We also looked at overall survival in the exercise group and health education group, and the 8-year overall survival was 90.3% in the exercise group and 83.2% in the health education group. So this was a difference of 7.1%. Still statistically significant. I think this was really a fantastic effort over more than a decade at over 50 institutions with almost 900 patients, really done in a very systematic, high-intervention way that showed a fantastic result. Absolutely generalizable for patients with colon cancer. We have hints in other cancers that this is beneficial, and frankly, for our patients for other comorbidities, such as cardiovascular, etc., I really think that this is an abstract that deserved the press that it received. Dr. Sweetenham: Yeah, absolutely, and it is going to be very interesting, I think, over the next 2 or 3 years to see how much impact this particular study might have on programs across the country and across the world actually, in terms of what they do in this kind of adjuvant setting for structured exercise. Dr. Hamilton: Absolutely.  So let's move on to Abstract 3006. This was an NCI-led effort comparing genomic testing using ctDNA and tissue from patients with less common cancers who were enrolled in but not eligible for a treatment arm of the NCI-MATCH trial. Tell us about your takeaways from this study. Dr. Sweetenham: Yeah, so I thought this was a really interesting study based, as you said, on NCI-MATCH. And many of the listeners will probably remember that the original NCI-MATCH study screened almost 6,000 patients to assess eligibility for those who had an actionable mutation. And it turned out that about 60% of the patients who went on to the study had less common tumors, which were defined as anything other than colon, rectum, breast, non–small cell lung cancer, or prostate cancer. And most of those patients lacked an eligible mutation of interest and so didn't get onto a trial therapy. But with a great deal of foresight, the study group had actually collected plasma samples from these patients so that they would have the opportunity to look at circulating tumor DNA profiles with the potential being that this might be another way for testing for clinically relevant mutations in some of these less common cancer types. So initially, they tested more than 2,000 patients, and to make a somewhat complicated story short, there was a subset of five histologies with a larger representation in terms of sample size. And these were cholangiocarcinoma, small cell lung cancer, esophageal cancer, pancreatic, and salivary gland cancer. And in those particular tumors, when they compared the ctDNA sequencing with the original tumor, there was a concordance there of around 84%, 85%. And in the presentation, the investigators go on to list the specific mutated genes that were identified in each of those tumors. But I think that the other compelling part of this study from my perspective was not just that concordance, which suggests that there's an opportunity there for the use of ctDNA instead of tumor biopsies in some of these situations, but what was also interesting was the fact that there were several clinically relevant mutations which were detected only in the circulating tumor DNA. And a couple of examples of those included IDH1 for cholangiocarcinoma, BRAF and p53 in several histologies, and microsatellite instability was most prevalent in small cell lung cancer in the ctDNA. So I think that what this demonstrates is that liquid biopsy is certainly a viable screening option for patients who are being assessed for matching for targeted therapies in clinical trials. The fact that some of these mutations were only seen in the ctDNA and not in the primary tumor specimen certainly suggests that there's some tumor heterogeneity. But I think that for me, the most compelling part of this study was the fact that many of these mutations were only picked up in the plasma. And so, as the authors concluded, they believe that a comprehensive gene profiling with circulating tumor DNA probably should be included as a primary screening modality in future trials of targeted therapy of this type. Dr. Hamilton: Yeah, I think that that's really interesting and mirrors a lot of data that we've been seeing. At least in breast cancer, you know, we still do a biopsy up front to make sure that our markers, we're still treating the right disease that we think we are. But it really speaks to the utility of using ctDNA for serial monitoring and the emergence of mutations. Dr. Sweetenham: Absolutely. And you mentioned breast cancer, and so I'd like to dwell on that for a moment here because obviously, there was a huge amount of exciting breast cancer data presented at the meeting this year. And in particular, I'd like to ask you about LBA1008, the DESTINY-Breast09 clinical trial, which I think has the potential to establish a new first-line standard of care for metastatic HER2+ breast cancer. And that's an area where we haven't seen a whole lot of innovation for around a decade now. So can you give us some of the highlights of this trial and what your thinking is, having seen the results? Dr. Hamilton: Yeah, absolutely. So this was a trial in the first-line metastatic HER2 setting. So this was looking at trastuzumab deruxtecan. We certainly have had no shortage of reports around this drug, initially approved for later lines. DESTINY-Breast03 brought it into our second-line setting for HER2+ disease and we're now looking at DESTINY-Breast09 in first-line. So this actually was a 3-arm trial where patients were randomized 1:1:1 against standard taxane/trastuzumab/pertuzumab in one arm; trastuzumab deruxtecan with pertuzumab in another arm; and then a third arm, trastuzumab deruxtecan alone. And what we did not see reported was that trastuzumab deruxtecan-alone arm. But we did have reports from the trastuzumab deruxtecan plus pertuzumab versus the chemo/trastuzumab/pertuzumab. And what we saw was a statistically significant improvement in median progression-free survival, 26.9 months up to 40.7, so an improvement of 13.8 months, over a year in PFS. Not to mention that we're now in the 40-month range for PFS in first-line disease. Really, across all subgroups, we really weren't able to pick out a subset of patients that did not benefit. We did see about a 12% ILD rate with trastuzumab deruxtecan. That really is on par with what we've seen in other studies, around 10%-15%. I think that this is going to become a new standard of care in the first-line. I think it did leave some unanswered questions. We saw some data from the PATINA trial this past San Antonio Breast, looking at the addition of endocrine therapy with or without a CDK4/6 inhibitor, palbociclib, for those patients that also have ER+ disease, after taxane has dropped out in the first-line setting. So how we're going to kind of merge all this together is, I suspect that there are going to be patients that we or they just don't have the appetite to continue 3 to 4 years of trastuzumab deruxtecan. And so we're probably going to be looking at a maintenance-type strategy for them, maybe integrating the PATINA data there. But how we really put this into practice in the first-line setting and if or when we think about de-escalating down from trastuzumab deruxtecan to antibody therapy are some lingering questions. Dr. Sweetenham: Okay, so certainly is going to influence practice, but watch this space for a little bit longer, it sounds as though that's what you're saying. Dr. Hamilton: Absolutely.  So let's move on to GI cancer. Abstract 4006 reported preliminary results from the randomized phase 2 study of elraglusib in combination with gemcitabine/nab-paclitaxel versus the chemo gemcitabine/nab-paclitaxel alone in patients with previously untreated metastatic pancreatic cancer. Can you tell us more about this study? Dr. Sweetenham: Yeah, absolutely. As you mentioned, elraglusib is actually a first-in-class inhibitor of GSK3-beta, which has multiple potential actions in pancreatic cancer. But the drug itself may be involved in mediating drug resistance as well as in some tumor immune response modulation. Some of that's not clearly understood, I believe, right now. But certainly, preclinical data suggests that the drug may be effective in preclinical models and may also be effective in combination with chemotherapy and potentially with immune-modulating agents as well. So this particular study, as you said, was an open-label, randomized phase 2 study in which patients with pancreatic cancer were randomized 2:1 in favor of the elraglusib plus GMP—gemcitabine and nab-paclitaxel—versus the chemotherapy alone. And upon completion of the study, which is not right now, median overall survival was the primary end point, but there are a number of other end points which I'll talk about in just a moment. But the sample size was planned to be around 207 patients. The primary analysis included 155 patients in the combination arm versus 78 patients in the gemcitabine/nab-paclitaxel arm. Overall, the 1-year overall survival rate was 44.1% for the patients in the elraglusib-containing arm versus 23.0% in the patients receiving gemcitabine/nab-paclitaxel only. When they look at the median overall survival, it was 9.3 months for the experimental arm versus 7.2 months for chemotherapy alone. So put another way, there's around a 37% reduction in the risk of death with the use of this combination arm. The treatment was overall well-tolerated. There were some issues with grade 1 to 2 transient visual impairment in a large proportion of the patients. The most common treatment-related adverse effects with the elraglusib/GMP combination was transient visual impairment, which affected around 60% of the patients. Most of the more serious treatment-related adverse events included neutropenia, anemia, and fatigue in 50%, 25%, and 16% of the patients, respectively. So the early results from this study show a significant benefit for 1-year overall survival and for median overall survival with, as I mentioned above, a significant reduction in the risk of death. The authors went on to mention that the median overall survival for the control arm in this study is somewhat lower than in other comparable trials, but they think that this may be related to a more advanced disease burden in this particular study. Of interest to me was that right now: there is no apparent difference in progression-free survival between the 2 arms of this study. The authors described this as potentially indicating that this may be related in some way to immune modulation and immune effects on the tumor, which, if I'm completely honest, I don't totally understand. And so, the improvement in overall survival, as far as I can see at the moment, is not matched by an improvement in progression-free survival. So I think we probably need to wait for more time to elapse to see what happens with the study. And so, I think it certainly is an interesting study, and the results are intriguing, but I think it's probably a little early for it to actually shift the treatment paradigm in this disease. Dr. Hamilton: Fantastic. I think we've been waiting for advances in pancreatic cancer for a long time, but this, not unlike others, we learn more and then learn more we don't realize, so. Dr. Sweetenham: Right. Let's shift gears at this point and talk about a couple of other abstracts in kind of a very different space. Let's start out with symptom management for older adults with cancer. We know that undertreated symptoms are common among the older patient population, and Abstract 11002 reported on a randomized trial that demonstrated the effects of remote monitoring for older patients with cancer in terms of kind of symptoms and so on. Can you tell us a little bit about this study and whether you think this approach will potentially improve care for older patients? Dr. Hamilton: Yeah, I really liked this abstract. It was conducted through the Veterans Affairs, and it was based in California, which I'm telling you that because it's going to have a little bit of an implication later on. But essentially, adults that were 75 years or older who were Medicare Advantage beneficiaries were eligible to participate. Forty-three clinics in Southern California and Arizona, and patients were randomized either into a control group of usual clinic care alone, or an intervention group, which was usual care plus a lay health worker-led proactive telephone-based weekly symptom assessment, and this was for 12 months using the validated Edmonton Symptom Assessment System. So, there was a planned enrollment of at least 200 patients in each group. They successfully met that. And this lay health worker reviewed assessments with a physician assistant, who conducted follow-up for symptoms that changed by 2 points from a prior assessment or were rated 4 or greater. So almost a triage system to figure out who needed to be reached out to and to kind of work on symptoms. What I thought was fantastic about this was it was very representative of where it enrolled. There were actually about 50% of patients enrolled here that were Hispanic or Latinos. So some of our underserved populations and really across a wide variety of tumor types. They found that the intervention group had 53% lower odds of emergency room use, 68% lower odds of hospital use than the control group. And when they translated this to actual total cost of care, this was a savings of about $12,000 U.S. per participant and 75% lower odds of a death in an acute care facility. So I thought this was really interesting for a variety of reasons. One, certainly health care utilization and cost, but even more so, I think any of our patients would want to prevent hospitalizations and ER visits. Normally, that's not a fantastic experience having to feel poorly enough that you're in the emergency room or the hospital. And really showing in kind of concrete metrics that we were able to decrease this with this intervention. In terms of sustainability and scalability, I think the question is really the workforce to do this. Obviously, you know, this is going to take dedicated employees to have the ability to reach out to these patients, etc., but I think in value-based care, there's definitely a possibility of having reimbursement and having the funds to institute a program like this. So, definitely thought-provoking, and I hope it leads to more interventions. Dr. Sweetenham: Yeah, we've seen, over several years now, many of these studies which have looked at remote symptom monitoring and so on in this patient population, and many of them do show benefits for that in kinds of end points, not the least in this study being hospitalization and emergency room avoidance. But I think the scalability and personnel issue is a huge one, and I do wonder at some level whether we may see some AI-based platforms coming along that could actually help with this and provide interactions with these patients outside of actual real people, or at least in combination with real people. Dr. Hamilton: Yeah, that's a fantastic point.  So let's talk a little bit about clinical trials. So eligibility assessment for oncology clinical trials, or prescreening, really relies on manual review of unstructured clinical notes. It's time-consuming, it's prone to errors, and Abstract 1508 reported on the final analysis of a randomized trial that looked at the effect of human-AI teams prescreening for clinical trial eligibility versus human-only or AI-only prescreening. So give us more good news about AI. What did the study find? Dr. Sweetenham: Yeah, this is a really, a really interesting study. And of course, any of us who have ever been involved in clinical trials will know that accrual is always a problem. And I think most centers have attempted, and some quite successfully managed to develop prescreening programs so that patients are screened by a health care provider or health care worker prior to being seen in the clinic, and the clinical investigator will then already know whether they're going to be eligible for a trial or not. But as you've already said, it's a slow process. It's typically somewhat inefficient and requires a lot of time on the part of the health care workers to actually do this in a successful way. And so, this was a study from Emory University where they took three models of ways in which they could assess the accuracy of the prescreening of charts for patients who are going to be considered for clinical trials. One of these was essentially the regular way of having two research coordinators physically abstract the charts. The second one was an AI platform which would extract longitudinal EHR data. And then the third one was a combination of the two. So the AI would be augmented by the research coordinator or the other way around. As a gold standard, they had three independent oncology reviewers who went through all of these charts to provide what they regarded as being the benchmark for accuracy. In a way, it's not a surprise to me because I think that a number of other systems which have used this combination of human verification of AI-based tools, it actually ultimately concluded that the combination of the two in terms of chart accuracy was for the most part better than either one individually, either the research coordinator or the AI alone. So I'll give you just a few examples of where specifically that mattered. The human plus AI platform was more accurate in terms of tumor staging, in terms of identifying biomarker testing and biomarker results, as well as biomarker interpretation, and was also superior in terms of listing medications. There are one or two other areas where either the AI alone was somewhat more accurate, but the significant differences were very much in favor of a combination of human + AI screening of these patient charts. So, in full disclosure, this didn't save time, but what the authors reported was that there were definite efficiency gains, and presumably this would actually become even more improved once the research coordinators were somewhat more comfortable and at home with the AI tool. So, I thought it was an interesting way of trying to enhance clinical trial accrual up front by this combination of humans and technology, and I think it's going to be interesting to see if this gets adopted at other centers in the future. Dr. Hamilton: Yeah, I think it's really fascinating, all the different places that we can be using AI, and I love the takeaway that AI and humans together are better than either individually. Dr. Sweetenham: Absolutely.  Thanks once again, Dr. Hamilton, for sharing your insights with us today and for all of the incredible work you did to build a robust program. And also, congratulations on what was, I think, a really remarkable ASCO this year, one of the most exciting for some time, I think. So thank you again for that. Dr. Hamilton: Thanks so much. It was really a pleasure to work on ASCO 2025 this year. Dr. Sweetenham: And thank you to our listeners for joining us today. You'll find links to all the abstracts we discussed today in the transcript of this episode. Be sure to catch up on all of our coverage from the Annual Meeting. You can catch up on my daily reports that were published each day of the Annual Meeting, featuring the key science and innovations presented. And we'll have wrap-up episodes publishing in June, covering the full spectrum of malignancies from ASCO25. If you value the insights you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose    Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

ESC TV Today – Your Cardiovascular News
Season 3 - Ep.18: Heart disease risk: Framingham Heart Study insights - Sudden death in female athletes

ESC TV Today – Your Cardiovascular News

Play Episode Listen Later Jun 19, 2025 25:48


This episode covers: Cardiology This Week: A concise summary of recent studies Heart disease risk: Framingham Heart Study insights Sudden death in female athletes Mythbusters: Owning a pet reduces the risk of heart disease Host: Susanna Price Guests: Carlos Aguiar, Sabiha Gati, Vasan Ramachandran Want to watch that episode? Go to: https://esc365.escardio.org/event/1809 Want to watch that extended interview on sudden death in athletes? Go to: https://esc365.escardio.org/event/1809?resource=interview   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. The ESC is not liable for any translated content of this video.The English-language always prevails. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Sabiha Gati, Nicolle Kraenkel, Susanna Price and Vasan Ramachandran have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

ESC TV Today – Your Cardiovascular News
Season 3 - Ep.18: Extended interview on sudden death in athletes

ESC TV Today – Your Cardiovascular News

Play Episode Listen Later Jun 19, 2025 10:01


Host: Susanna Price Guest: Sabiha Gati Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1809?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/1809   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Sabiha Gati, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Der Springer Medizin Podcast
Polycythaemia vera: seltene Diagnose mit interdisziplinärem Versogungsauftrag (gesponsert von Novartis Pharma GmbH)

Der Springer Medizin Podcast

Play Episode Listen Later Jun 19, 2025 23:31


Oft bereits Jahre vor der Diagnose weisen atypische Thrombosen, ein Herzinfarkt oder ein Schlaganfall darauf hin, was eigentlich nicht in Ordnung ist: zu viele Erythrozyten im Blut, zu viele Granulozyten, zu viele Blutplättchen. Die Rede ist von Polycythaemia vera, einer seltenen Blutkrebserkrankung. Die Diagnose wird oft spät gestellt, die therapeutischen Möglichkeiten werden teils nicht ausgeschöpft. Dabei haben die Patientinnen und Patienten eigentlich eine recht gute Prognose.

MS-podden
83. MS, kroppen och livet, del 4

MS-podden

Play Episode Listen Later Jun 17, 2025 58:42


I den fjärde, och sista delen, av serien MS, kroppen och livet gästas jag av Katarina Fink som är neurolog och specialiserad på MS och graviditet och det är det som dagens avsnitt kommer att handla om inklusive amning. Vi har även med oss Louice på distans från Härjedalen som fick sin diagnos 2019 och som just nu befinner sig i sin andra graviditet.   Producerad på uppdrag från Novartis

MorningBull
La géopolitique s'enflamme, le pétrole aussi | Swiss Bliss

MorningBull

Play Episode Listen Later Jun 14, 2025 26:43


Pendant ce temps-là, la Bourse suisse vit sa vie : UBS râle, Swiss Re sort le chéquier, Novartis brille, et Dätwyler vire du monde, mais tout va bien — le S&P 500 est à 2% de ses plus hauts

The Lead Podcast presented by Heart Rhythm Society
The Lead Podcast - Episode 107: A Discussion of Catheter Ablation of AFib in Cardiac Sarcoidosis and Amyloidosis...

The Lead Podcast presented by Heart Rhythm Society

Play Episode Listen Later Jun 12, 2025 12:11


Join HRS Board Member Prashanthan Sanders, MBBS, PhD, FHRS (University of Adelaide) as he discusses this exciting paper, presented at Heart Rhythm 2025. He is joined in the Heart Rhythm Tv Studio in San Diego, California by Louise Segan, MBBS, MPH (Alfred Health), and Takanori Yamaguchi, MD, PhD (Saga University). This discussion took place on-site at Heart Rhythm 2025.   https://www.hrsonline.org/education/TheLead https://www.heartrhythmjournal.com/article/S1547-5271(25)01245-7/fulltext Host Disclosure(s): P. Sanders: Honoraria/Speaking/Consulting: Boston Scientific, Abbott Medical, Research: Boston Scientific, Abbott, Medtronic, Becton Dickinson, CathRx, Pacemate, Kalyan Technologies, Ceryx Medical, Biosense Webster, Inc., Hello Alfred, Abbott Medical Membership on Advisory Committees: Pacemate, Medtronic PLC, Boston Scientific, CathRx, Abbott Medical Contributor Disclosure(s): T. Yamaguchi: Honoraria/Speaking/Consulting: Abbott Japan, Biotronik, Boston Scientific, Abbott Medical, Japan Medtronic, Inc., Daiichi Sankyo, Novartis, Japan Lifeline, Nihon Kohden, Bayer Healthcare Pharmaceuticals Japan, Boehringer Ingelheim L. Segan: Nothing to disclose.

Oncologie Up-to-date
Huidige behandelopties voor patiënten met CLL

Oncologie Up-to-date

Play Episode Listen Later Jun 10, 2025 27:30


In deze podcast, mede mogelijk gemaakt door AstraZeneca en Beigene, spreekt wetenschapsjournalist Judith Cohen met prof. dr. Stephan Stilgenbauer (Universiteit Ulm, Duitsland) over de huidige eerstelijnsbehandelopties voor patiënten met CLL. Aan bod komen de belangrijkste punten van de meest recente richtlijnupdates en zijn ervaring met de behandeling van CLL-patiënten.Disclosures Prof. dr. Stephan Stilgenbauer: AbbVie, Amgen, AstraZeneca, BeiGene, BMS, Galapagos, Gilead, GSK, Hoffmann-La Roche, Johnson&Johnson, Lilly, Novartis, Sunesis.

PharmaSource Podcast
Digital Manufacturing Networks in the Real World

PharmaSource Podcast

Play Episode Listen Later Jun 8, 2025 29:00


At CDMO Live 2025, a panel sponsored by Aizon explored how pharma companies are transforming external manufacturing operations through digital integration, with experts from sharing practical approaches to implementation.The Digital Divide: Big Pharma vs Mid-Size PlayersThe panellists painted a stark contrast in digital maturity across the pharmaceutical manufacturing landscape. Dave O'Gara, pharmaceutical business consultant at Aizon with over 30 years experience at Novartis, outlined the current state of play."When you move into pharma and segregate into big pharma, they have digital strategies... When you move into the mid-range CDMOs and smaller CMOs, it's not so active," O'Gara explained, highlighting what he termed a "massive opportunity" for mid-size players.Franziskus Kath, founder of Kath-Consulting and former VP of Emerging Technology for QA at Johnson & Johnson, confirmed this assessment: "The larger the companies, the more digital is already there... Most of them have been for the past eight to 10 years really tackling the topic."From the CDMO perspective, Vishnu Dwadasi, Director of Life Sciences at West Monroe, described significant implementation challenges: "A lot of these companies are still very manual, so they have to move from paper to digital and then digital to eventually leveraging analytics and AI."Download the full report

The View on GU | with Lalani and Wallis
Episode 25: ASCO Annual Meeting 2025 Commentary: Bladder Cancer

The View on GU | with Lalani and Wallis

Play Episode Listen Later Jun 7, 2025 29:30


Concluding their three-episode series filmed live in Chicago, your hosts wrap up the weekend with a discussion of the key bladder cancer presentations from the 2025 ASCO Annual Meeting. They begin in the perioperative space, reviewing updated CREST data presented since AUA and revisiting the NIAGARA trial last seen at ESMO 2024, and end by covering the latest EV-302 updates in the metastatic setting.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.

The View on GU | with Lalani and Wallis
Episode 24: ASCO Annual Meeting 2025 Commentary: Prostate Cancer

The View on GU | with Lalani and Wallis

Play Episode Listen Later Jun 6, 2025 29:27


Picking up from Episode 23, your hosts turn their focus to the highly anticipated prostate cancer presentations from the 2025 ASCO Annual Meeting in Chicago. They begin with a discussion on mCSPC, focusing on the AMPLITUDE trial, followed by results from TALAPRO-2, the ARANOTE trial, IRONMAN, and STAMPEDE. The episode wraps with key abstracts and oral presentations on mCRPC.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.

ESC TV Today – Your Cardiovascular News
Season 3 - Ep.17: Coronary sinus reducer - Strategies to reach LDL cholesterol goals in high-risk patients

ESC TV Today – Your Cardiovascular News

Play Episode Listen Later Jun 5, 2025 21:26


This episode covers:  Cardiology this Week: A concise summary of recent studies Coronary sinus reducer: promise in refractory angina Best strategies to reach LDL cholesterol goals in high-risk patients Snapshots Host: Susanna Price Guests: Carlos Aguiar, Rasha Al-Lamee, J. Wouter Jukema, Steffen Petersen Want to watch that episode? Go to: https://esc365.escardio.org/event/1807 Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1807?resource=interview Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Rasha Al-Lamee has declared to have potential conflicts of interest to report: speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. J. Wouter Jukema has declared to have potential conflicts of interest to report: J. Wouter Jukema/his department has received research grants from and/or was speaker (CME accredited) meetings sponsored/supported by Abbott, Amarin, Amgen, Athera, Biotronik, Boston Scientific, Dalcor, Daiichi Sankyo, Edwards Lifesciences, GE Healthcare Johnson and Johnson, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis, Shockwave Medical, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Netherlands Heart Institute and the European Community Framework KP7 Programme. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

ESC TV Today – Your Cardiovascular News
Season 3 - Ep.17: Extended interview on strategies to reach LDL cholesterol goals in high-risk patients

ESC TV Today – Your Cardiovascular News

Play Episode Listen Later Jun 5, 2025 9:15


Host: Susanna Price Guest: J. Wouter Jukema Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1807?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/1807 Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. J. Wouter Jukema has declared to have potential conflicts of interest to report: J. Wouter Jukema/his department has received research grants from and/or was speaker (CME accredited) meetings sponsored/supported by Abbott, Amarin, Amgen, Athera, Biotronik, Boston Scientific, Dalcor, Daiichi Sankyo, Edwards Lifesciences, GE Healthcare Johnson and Johnson, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis,Shockwave Medical, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Netherlands Heart Institute and the European Community Framework KP7 Programme. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

The View on GU | with Lalani and Wallis
Episode 23: ASCO Annual Meeting 2025 Commentary: Kidney Cancer

The View on GU | with Lalani and Wallis

Play Episode Listen Later Jun 5, 2025 29:23


Recorded live in Chicago, your hosts explore the latest in kidney cancer, discussing new five-year follow-up data from KEYNOTE-564, the long-term results of CheckMate 214, insights from the ongoing PDIGREE trial, and much more.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.

Artificial Intelligence in Industry with Daniel Faggella
The Evolving Role of AI in Modernizing Clinical Trials - with Xiong Liu of Novartis

Artificial Intelligence in Industry with Daniel Faggella

Play Episode Listen Later Jun 4, 2025 28:29


Today's guest is Xiong Liu, Director of Data Science and AI at Novartis. Xiong returns to the platform in a special episode brought to you by Medable to explore the evolving role of AI in modernizing clinical trials. Their conversation covers how life sciences teams are leveraging AI to streamline data workflows, accelerate study readiness, and maintain regulatory compliance in both decentralized and traditional models. Throughout the episode, Xiong shares insights into the growing importance of integrating structured and unstructured data across trial systems — from clinical notes to imaging and lab results. This episode is sponsored by Medable. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast!

The EMG GOLD Podcast
S10 E01: GSK's Dheepa Chari on the evolving sphere of scientific communication

The EMG GOLD Podcast

Play Episode Listen Later Jun 4, 2025 28:11


The EMJ GOLD podcast is back for a new season! In the first episode of season 10, the team are joined by Dheepa Chari, Vice President and Head of Global Scientific Communications, GSK, to discuss the past, present and future of scientific communications. Together, Dheepa and Isabel explore her journey from biostatistics to biopharma leadership — and the lessons learned along the way. They discuss what great science communication looks like, where it's heading next and why storytelling still matters in a digital-first world. Plus, expect practical insights on cross-functional collaboration and the growing role of AI. A little more on EMJ GOLD's guest… Dheepa Chari is the Vice President and Head of Global Scientific Communications at GSK. Here, she leads strategy and execution across Oncology, Vaccines, Specialty Care and General Medicine, driving innovation in how scientific narratives are delivered across channels. Before joining GSK in 2024, Dheepa held senior posts at Pfizer, Amgen and Novartis in both clinical and communications roles. Outside of work, Dheepa brings stories to life in a different way - as a singer-songwriter who regularly performs in New York City.

Pharma and BioTech Daily
Pharma and Biotech Daily: Insider Trading, R&D Spending, and Acquisitions in the World of Pharmaceuticals

Pharma and BioTech Daily

Play Episode Listen Later May 29, 2025 1:59


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Former Chinook board member, Rouzbeh Haghighat, has been indicted for insider trading related to Novartis' $3.2 billion acquisition of the company. Despite this scandal, pharma R&D spending increased in 2024, climbing 1.5% across the global pharmaceutical sector. The acquisition of SiteOne by Lilly follows Vertex into the non-opioid pain space, providing diversification for Lilly, which has been focusing on obesity and diabetes treatments. Meanwhile, AbbVie's Allergan cuts over 200 staff after a botched marketing campaign, and Inflarx axes a rare skin disease study due to disappointing late-stage data.AGC Biologics will be at Bio International in Boston to showcase their global capabilities in drug production. Vaccine overhaul, rocket grounding, and drug price transparency are also highlighted in the latest news. Biogen's strategy for Zurzuvae shifts as obstetricians/gynecologists rise to the front lines. Drug price transparency in the US is discussed as being easier said than done. Additionally, Rocket's gene therapy for Danon disease is on hold after a patient death, and four biotechs are facing uncertainty in the COVID-19 vaccine landscape.Global pharmaceutical companies are increasing their research and development spending despite political and economic challenges. Biogen is shifting its strategy for the drug Zurzuvae as obstetricians and gynecologists become more involved. Drug price transparency in the US is still a challenge, despite efforts to increase transparency. Trilink has introduced a new poly(A) tail modification to enhance protein expression.In other news, a former Chinook board member has been indicted for insider trading, Trump has appointed Dr. Oz to lead drug pricing negotiations, and Lilly is following Vertex into non-opioid pain treatment with a SiteOne acquisition. Sanofi has purchased Vigil for $470 million to reignite an Alzheimer's target.

Artificial Intelligence in Industry with Daniel Faggella
Building Agile R&D Strategies Through Predictive Analytics - with Scott Bradley of Novartis

Artificial Intelligence in Industry with Daniel Faggella

Play Episode Listen Later May 22, 2025 19:26


In this episode of the ‘AI in Business' podcast, Scott Bradley, VP of AI and Innovation at Novartis, returns to discuss how AI is reshaping decision-making at the earliest stages of drug development—and what that means for the future of pharma investment strategy. Host Matthew DeMello and Scott explore how the pharmaceutical industry is transitioning from intuition-led portfolio choices to data-driven precision. They discuss the growing influence of AI in identifying viable drug candidates, designing complex proteins, and even solving long-standing manufacturing challenges. Scott also highlights the impact of AI on shifting portfolio dynamics—enabling pharma companies to target smaller, more specific patient populations and scale up development across a wider range of therapies. With AI now central to everything from molecule discovery to commercialization, the conversation offers a window into how life sciences organizations must adapt both structurally and strategically to stay competitive. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast! This episode is sponsored by Intelligencia AI. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1.

ASCO Daily News
ASCO25 Preview: Key Research Accelerating Cancer Care

ASCO Daily News

Play Episode Listen Later May 22, 2025 20:42


Dr. John Sweetenham and Dr. Erika Hamilton discuss top abstracts that will be presented at the 2025 ASCO Annual Meeting, including research on tech innovations that could shape the future of oncology. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'm delighted to be joined today by Dr. Erika Hamilton, a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Hamilton is also the chair of the 2025 ASCO Annual Meeting Scientific Program, and she's here to tell us about some of the key abstracts, hot topics, and novel approaches in cancer care that will be featured at this year's Annual Meeting. Our full disclosures are available in the transcript of this episode. Dr. Hamilton, it's great to have you on the podcast today, and thanks so much for being here. Dr. Erika Hamilton: Thanks, Dr. Sweetenham. I'm glad to be here. Dr. John Sweetenham: Dr. Hamilton, the Presidential Theme of the Annual Meeting this year is ‘Driving Knowledge to Action: Building a Better Future,' and that's reflected in many of the sessions that will focus on action-oriented guidance to improve care for our patients. And as always, there'll be great presentations on practice-changing abstracts that will change treatment paradigms and transform care. Can you tell us about some of the hot topics this year and what you're particularly excited about? Dr. Erika Hamilton: You're right. Dr. Robin Zon's theme is ‘Driving Knowledge to Action: Building a Better Future,' and you're going to see that theme really interlaced throughout the ASCO program this year. We had a record number of submissions. Over 5,000 abstracts will be published, and there'll be about 3,000 presentations, either in oral format or poster presentations. We have 200 dynamic sessions. Many of the discussants will be highlighting key takeaways and how we can translate action-oriented guidance to better treat our patients to build a better future. Our state-of-the-art science will include a Plenary Session. This will feature presentations as well as discussion of each of the presentations for clinical late-breaking abstracts. We have Clinical Science Symposia that I'm particularly excited about this year. These will feature key abstracts as well as discussions and a foundational talk around the subject. We're covering novel antibody-drug conjugate targets, turning “cold” tumors “hot” to include CAR T, as well as the future of cancer detection. There'll be rapid oral abstracts, case-based panels, and this will also feature interactive audience polling and case discussions. I also want to highlight the community connection opportunities. There will be 13 Communities of Practice that will be meeting on-site during ASCO, and there's also really a plethora of networking opportunities for trainees and early-career professionals, a Women's Networking Center, a patient advocate space, and I'm happy to report there will also be live music out on the terrace this year at ASCO. Dr. John Sweetenham: Well, that's going to be a really great addition. I have to say, I think this is always a special time of year because excitement starts to mount as the meeting gets closer and closer. And once the abstracts are out there, I certainly personally feel that the excitement builds. Talking of abstracts, let's dive into some of the key abstracts for this year's meeting. I'd like to start out by asking you about Abstract 505. This reports on 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer in the SOFT and TEXT trials. It assesses the benefits of adjuvant exemestane and ovarian function suppression or tamoxifen and ovarian function suppression. So, could you talk us through this and tell us what you think the key takeaways from this abstract are? Dr. Erika Hamilton: Absolutely. This is essentially the SOFT and TEXT trials. They are trials that we've been following for quite some time, evidenced by the 15-year outcome. And I think it really answers two very important questions for us regarding adjuvant endocrine therapy for patients that are facing hormone receptor-positive disease. The benefit of ovarian function suppression for one, and then second, the benefit of exemestane over tamoxifen, which is our SERM [selective estrogen receptor modulator]. So, in terms of the SOFT trial, when we talk about distance recurrence-free interval, which I really think is probably the most meaningful because secondary cancers, et cetera, are not really what we're getting at here. But in terms of distant recurrence-free interval, certainly with tamoxifen, using tamoxifen plus ovarian function suppression adds a little bit. But where we really get additional benefits are by moving to exemestane, an aromatase inhibitor with the ovarian function suppression. So, for example, in SOFT, for distant recurrence-free interval for patients that have received prior chemotherapy, the distance recurrence-free interval was 73.5% with tamoxifen, bumped up just a tiny bit to 73.8% with ovarian function suppression. But when we used both ovarian function suppression and switched to that aromatase inhibitor, we're now talking about 77.6%. It may seem like these are small numbers, but when we talk about an absolute benefit of 4%, these are the type of decisions that we decide whether to offer chemotherapy based on. So, really just optimizing endocrine therapy really can provide additional benefits for these patients. Just briefly, when we turn to TEXT, similarly, when we look at distance recurrence-free interval for our patients that are at highest risk and receive chemotherapy, tamoxifen and ovarian function suppression, 79%; 81% with exemestane and ovarian function suppression. And when we talk about our patients that did not receive chemotherapy, it increased from 91.6% up to 94.6%—very similar that 3% to 4% number. So, I think that this is just very important information when counseling our patients about the decisions that they're going to make for themselves in the adjuvant setting and how much we want to optimize endocrine therapy. Dr. John Sweetenham: Thanks so much for your insight into that. Dr. Erika Hamilton: Yeah, absolutely. So, let's turn to hematologic malignancies. Abstract 6506 reports exciting results on the new agent ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia. This is a phase 1b clinical activity study and safety results. This was the pivotal KOMET-001 study. And my question is, will this new agent fulfill an unmet need in this NPM1 space? Dr. John Sweetenham: Yeah, great question. And I think the answer is almost certainly ‘yes'. So, just as some brief background, NPM1 mutation is known to be a driver of leukemogenesis in around 30% of patients with AML, and it's a poor prognostic factor. And typically, about 50% of these patients will relapse within a year of their first-line therapy, and only around 10% of them will get a subsequent complete remission with salvage therapy. Menin inhibitors, which disrupt the interaction between menin and KMT2A, are known to be active in NPM1-mutated as well as in KMT2A-rearranged AML. And ziftomenib is a selective oral menin inhibitor, which in this study was evaluated at a dose of 600 mg once a day, as you mentioned, a phase 1b/2 study, which is multicenter and presented by Dr. Eunice Wang from Roswell Park. It's a relatively large study of 112 patients who were treated with this standard dose with relatively short median follow-up at this time. The median age was 69 years, and median prior therapies were two, but with a range of one to seven. And I think very importantly, 60% of these patients had previously been treated with venetoclax, and 23% of them had had a prior transplant. Looking at the results overall for this study, the overall response rate was 35%, which is actually quite impressive. Specifically for those patients in the phase 2 part of the study, around 23% achieved a CR [complete remission] or CRh [complete remission with partial hematologic recovery]. What's very interesting in my mind is that the response rates were comparable in venetoclax-naive and venetoclax-exposed patients. And the drug was very well tolerated, with only 3% of patients having to discontinue because of treatment-related adverse events. And I think the authors appropriately conclude that, first of all, the phase 2 primary endpoint in the study was met, and that ziftomenib achieved deep and durable responses in relapsed and refractory NPM1-mutated AML, regardless of prior venetoclax, with good tolerance of the drug. And so, I think putting all of this together, undoubtedly, these data do support the potential use of this agent as monotherapy and as a new option for those patients who have relapsed or refractory NPM1-mutated acute myeloid leukemia. So, let's move on a little bit more now and change the subject and change gears completely and talk about circulating tumor DNA [ctDNA]. This has been a hot topic over a number of years now, and at this year's meeting, there are quite a few impactful studies on the use of ctDNA. We have time to focus on just one of these, and I wanted to get your thoughts on Abstract 4503. This is from the NIAGARA trial, which looks at ctDNA in patients with muscle-invasive bladder cancer who receive perioperative durvalumab. Could you tell us a little bit about this study? Dr. Erika Hamilton: So, this was the phase 3 NIAGARA trial, and this is literally looking for patients with muscle-invasive bladder cancer that are cisplatin-eligible, and the addition of durvalumab to neoadjuvant chemotherapy. So here, this is a planned exploratory analysis of ctDNA and the association with clinical outcomes from NIAGARA. So, this is really the type of study that helps us determine which of our patients are more likely to have a good outcome and which of our patients are more likely not to. There were 1,000 randomized patients in this study, and 462 comprised the biomarker-evaluable population. There were about half in the control arm and half in the durvalumab arm. And overall, the ctDNA-positive rate at baseline was about 57%, or a little over half, and that had decreased to about 22% after neoadjuvant treatment. ctDNA clearance rates from baseline to pre-radical cystectomy was about 41% among those with durvalumab and 31% among those in control. And the non-pCR rate was 97% among patients with pre-cystectomy ctDNA-positive status. So, this really gives us some information about predicting who is going to have better outcomes here. We did see a disease-free survival benefit with perioperative durvalumab, and this was observed in post-cystectomy ctDNA-positive as well as the ctDNA-negative groups. Shifting gears now to GI cancer, Abstract 3506 is a long-term safety and efficacy study of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer. And this is the CodeBreaK-101 study. What are your thoughts on this study? Dr. John Sweetenham: Yeah, thanks. A very interesting study, and this abstract builds upon the phase 3 CodeBreaK-300 trial, which I think has just been published in the Journal of Clinical Oncology. This showed that the combination of sotorasib and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer. The current abstract, as you mentioned, reports the CodeBreaK-101 trial. And this was a phase 1b trial where FOLFIRI therapy was added to sotorasib and panitumumab in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer. The abstract reports the overall and progression-free survival results, as well as some updated safety and response data. So, in this study, patients with this particular mutation who had received at least one prior systemic treatment but were KRAS G12C inhibitor-naive were enrolled into an expansion cohort of the CodeBreaK-101 protocol. And these patients received what apparently now recommended as the standard phase 2 dose of sotorasib of 960 mg daily, plus panitumumab and a standard dose of FOLFIRI. And the primary endpoint of the study was safety, and secondary endpoints included confirmed response, overall response, and progression-free survival, as assessed by the investigator. And by November of last year, 40 patients had been enrolled into this study. Common treatment-related adverse events were cutaneous; some patients developed neutropenia, and stomatitis was fairly widespread. Discontinuation of sotorasib because of adverse events was only seen in 1% of patients, although patients did have to discontinue because of toxicity from some of the other agents in the combination. Looking at the results of this study, the updated objective response rate was 57.5%, and the disease control rate was estimated at 92%, going on 93%, with a median time to response of 1.6 months and a median response duration of 6 months. After a median follow-up of 29.2 months, the median progression-free survival was 8.2 months, and the overall survival 17.9 months. So, the authors have concluded that this combination, including sotorasib, panitumumab, and FOLFIRI, does appear to show quite promising long-term efficacy in pretreated patients with this specific mutation. The ongoing phase 3 study they mentioned, CodeBreaK-301, is aiming to evaluate this combination against the standard of care in the first-line setting for patients with KRAS G12C-mutated colorectal cancer. So, promising results, and we'd be very interested to see how this particular combination performs in the frontline. Dr. Erika Hamilton: Fantastic. Thanks so much for sharing that. Let's shift gears again and really talk about digital technology. I feel that we're all going to have to get much better with this, and really, there are a lot of promises for our patients coming here. There are a lot of abstracts at ASCO that are focusing on innovations in digital technology, including a really interesting psychosocial digital application for caregivers of patients that are undergoing hematopoietic stem cell transplantation. Can you tell us a little bit about this? It's Abstract 11000. Dr. John Sweetenham: Yeah, absolutely. This abstract certainly caught my eye, and I think it's intriguing for a number of reasons, partly because it's app-based, and partly also because it specifically addresses caregiver burden and caregiver needs in the oncology setting, which I think is especially important. And although the context, the clinical context of this study, is hematopoietic stem cell transplantation, I think it has potential applications way beyond that. We all know that caregivers of patients undergoing stem cell transplantation have significant quality-of-life struggles. They are well-documented to have significant psychological and emotional strain before, during, and after stem cell transplantation. And this abstract describes an application called BMT-CARE, which is aimed at improving caregivers' quality of life, caregiver burden, mood symptoms, and coping skills, and so on. So, this was a single-center, randomized trial from MGH [Massachusetts General Hospital] of this app for stem cell transplant caregivers, compared with usual care in those individuals. And the eligible patients, or eligible individuals, were adults caring for patients with heme malignancy undergoing either an autologous or an allogeneic stem cell transplant. Patients were randomly assigned either to use the app or for usual care. And the app itself—and I think it'll be interesting to actually see this at the meeting and visualize it and see how user-friendly and so on it is—but it comprises five modules, which integrate psychoeducation, behavior change, stress management, and they're delivered through a kind of interactive platform of educational games and videos. And then participants were self-reporting at baseline and then 60 days after transplant. So, around 125 patients were enrolled in this study, of around 174 who were initially approached. So, just over 70% uptake from caregivers, which is, I think, relatively high, and evenly distributed between the two randomized arms. And the majority of the participants were spouses. And at 60 days post-stem cell transplant, the intervention participants reported a better quality of life compared with those who received usual care. If you break this down a little bit more, these participants reported lower caregiving burden, lower incidence of depression, fewer PTSD symptoms, and overall better coping skills. So, the authors conclude that this particular app, a digital health intervention, led to pretty substantial improvements in quality of life for these caregivers. So, intriguing. As I said, it'll be particularly interesting to see how this thing looks during the meeting. But if these kind of results can be reproduced, I think this sort of application has potential uses way beyond the stem cell transplant setting. Dr. Erika Hamilton: Yeah, I find that just so fascinating and very needed. I think that the caregiving role is often underestimated in how important that is for the patient and the whole family, and really giving our caregivers more tools in their toolbox certainly is quite helpful. Dr. John Sweetenham: Absolutely. Well, the meeting is getting closer, and as I mentioned earlier, I think anticipation is mounting. And I wanted to say thanks so much to you for chatting with me today about some of the interesting advances in oncology that we're going to see at this year's meeting. There is a great deal more to come. Our listeners can access links to the studies we've discussed today in the transcript of this episode. I'm also looking forward, Dr. Hamilton, to having you back on the podcast after the Annual Meeting to dive into some of the late-breaking abstracts and some of the other key science that's captured the headlines this year. So, thanks once again for joining me today. Dr. Erika Hamilton: Thanks so much for having me. Pleasure. Dr. John Sweetenham: And thank you to our listeners for joining us today. Be sure to catch my “Top Takeaways from ASCO25.” These are short episodes that will drop each day of the meeting at 5:30 p.m. Eastern Time. So, subscribe to the ASCO Daily News Podcast wherever you prefer to listen, and join me for concise analyses of the meeting's key abstracts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose  Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

ESC TV Today – Your Cardiovascular News
Season 3 - Ep.16: Extended interview on The role of cardiac magnetic resonance in myocardial disease 

ESC TV Today – Your Cardiovascular News

Play Episode Listen Later May 22, 2025 11:27


Host: Rick Grobbee Guest: Steffen Petersen Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1806?r Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Rick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

ESC TV Today – Your Cardiovascular News
Season 3 - Ep.16: The role of cardiac magnetic resonance in myocardial disease - Air pollution and heart disease

ESC TV Today – Your Cardiovascular News

Play Episode Listen Later May 22, 2025 25:29


This episode covers: Cardiology This Week: A concise summary of recent studies The role of cardiac magnetic resonance in myocardial disease Air pollution and heart disease Statistics Made Easy: Quasi-experimental study designs Host: Rick Grobbee Guests: Carlos Aguiar, Steffen Petersen, Mark Miller Want to watch that episode? Go to: https://esc365.escardio.org/event/1806 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Rick Grobbee, Nicolle Kraenkel and Mark Miller have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Pharma and BioTech Daily
Survival Strategies and Strategic Partnerships: The Latest in Pharma and Biotech

Pharma and BioTech Daily

Play Episode Listen Later May 22, 2025 1:45


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Moderna has withdrawn its application for a combination flu and COVID-19 vaccine after discussions with the FDA. The vaccine had shown efficacy in eliciting antibodies, but the company decided to pull the application. In the biotech market, executives from NextGen companies discussed strategies for surviving in what they described as a "moribund" market during a webinar. Biospace's nextgen companies are thriving in a challenging biotech market. Executives discuss survival strategies in the webinar "Are We There Yet?" Pfizer's $6 billion China deal stands out in a competitive market, with Novartis' $4 billion partnership following closely. Biopharma companies are facing pressure to cut assets early due to rising development costs and regulatory hurdles. Lotte Biologics offers specialized end-to-end services at its ADC facility in Syracuse, NY. Other top stories include the FDA's new risk-based approach to COVID-19 vaccines, Genentech's investment in Orionis, and Bio-Rad's new center for excellence for biotherapeutic antibody discovery. Roche's Genentech recently did not win adcomm backing for an expansion. Pfizer has made a deal in China, and RFK claims ignorance about HHS research cuts during a hearing. The top 5 most active corporate VCs in pharma are also highlighted. Additionally, upcoming events and job opportunities in the biotech industry are featured.In conclusion, the biotech market is presenting challenges for companies, but there are opportunities for growth and strategic partnerships. Stay tuned for more updates on regulatory changes, investment deals, and industry trends in the world of Pharma and Biotech. Thank you for listening to Pharma and Biotech daily.

OncLive® On Air
S13 Ep2: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

OncLive® On Air

Play Episode Listen Later May 19, 2025 49:30


This featured podcast includes a discussion with 3 experts on managing patients with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC) from a satellite symposium held in conjunction with the 42nd Annual Miami Breast Cancer Conference® in March 2025. In observational studies of treatment patterns in older women with mBC, approximately half of the patients were undertreated, and only half received a CDK4/6 inhibitor (CDK4/6i)-based regimen in the first-line setting. Reasons for undertreatment include concerns about the patient's age, perceived frailty, and underlying health issues. Aging is a heterogeneous process; older patients must receive individualized treatment that is not based solely on their age but on a comprehensive assessment that objectively assesses their overall health and ability to tolerate treatment. This program is designed to help clinicians assess the fitness of older patients with HR+/HER2– mBC, review the efficacy and safety of CDK4/6i in this patient population, and individualize treatment decision-making appropriately. Acknowledgment of Educational Grant Support This activity is supported by an educational grant from Pfizer Inc. Today's faculty are: Hope S. Rugo, MD Director, Women's Cancers Program Division Chief, Breast Medical Oncology Professor, Department of Medical Oncology & Therapeutics Research City of Hope Comprehensive Cancer Center Duarte, CA Professor Emeritus, UCSF Disclosures: Grant/Research Support: Ambrx; AstraZeneca; Daiichi Sankyo, Inc; F. Hoffmann-La Roche AG/Genentech, Inc; Gilead Sciences, Inc; Lilly; Merck & Co., Inc; Novartis Pharmaceuticals Corporation; OBI Pharma; Pfizer; Stemline Therapeutics. Consultant: Napo Therapeutics; Puma Biotechnology; Sanofi. Honoraria: Chugai; Mylan/Viatris. Neil M. Iyengar, MD Associate Attending, Breast Medicine Service Program Lead, MSK Healthy Living Department of Medicine Memorial Sloan Kettering Cancer Center Associate Professor of Medicine Weill Cornell Medical College New York, NY Disclosures: Consultant/Adviser: Arvinas, AstraZeneca, BD Life Sciences, Daiichi Sankyo, Genentech/Roche, Gilead, Menarini-Stemline, Novartis, Pfizer, Puma, Seagen, TerSera Therapeutics. Speaker: Cardinal Health, Curio Sciences, DAVA Oncology, IntrinsiQ Health. Editorial Position: npj Breast Cancer, Oncology®. Equity/Ownership: Complement Theory, Bettering Company. Research Support (to institution): American Cancer Society, Breast Cancer Research Foundation, Conquer Cancer Foundation, Kat's Ribbon of Hope, National Cancer Institute/National Institutes of Health. Contracted Research: Novartis, SynDevRx. Komal Jhaveri, MD, FACP Patricia and James Cayne Chair for Junior Faculty Associate Attending Physician, Breast Medicine Service and Early Drug Development Service Section Head, Endocrine Therapy Research Program Clinical Director, Early Drug Development Service Memorial Sloan Kettering Cancer Center Associate Professor of Clinical Medicine Weill Cornell Medical College New York, NY Disclosures: Consultant/Advisory Board: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jounce Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Menarini Group, Novartis, Olema Oncology, Pfizer Inc, Scorpion Therapeutics, Seagen Inc, Stemline Therapeutics Inc, Sun Pharma Advanced Research Company Ltd, Taiho Oncology Inc. Research Funding: AstraZeneca Pharmaceuticals LP, Debiopharm, Genentech, a member of the Roche Group, Gilead Sciences Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc, Scorpion Therapeutics, Zymeworks Inc. The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with ineligible companies. PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process. Off-Label Disclosure and Disclaimer This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Adpodcast
German Dziebel - Chief Innovation and Strategy Officer / Briolink AI

Adpodcast

Play Episode Listen Later May 17, 2025 13:10


German is a practitioner of "mixed cognitive arts" building modern brands across a full spectrum of categories (with a leaning toward health, pharma, wellness, beauty, finance, insurance, food, hospitality, sports and automotive).A Silicon Valley-trained entrepreneur and thought leader applying ingenuity and leading methodologies to simplify marketing challenges using human insights, cultural trends, lateral thinking and new technologies.A passionate advocate for anthropology bringing ethnographies, artificial intelligence, expert crowdsourcing and cultural computing to advertising, media, innovation and corporate strategy. A client-savvy executive building long-lasting client relationships and driving high-profile pitch wins and account retention for agencies.A visionary team architect mentoring talent, rejuvenating culture and shaping the future of the Strategy & Planning discipline.Feeling at home in both disruptive and mainstream agencies with a preference for the former.Brands: Procter & Gamble, Unilever, Intel, NASDAQ, Ask.com, Creditcards.com, Ely Lilly, AMGEN, Novartis, Pfizer, Otsuka, Kyowa Kirin, Ipsen, Stryker, Foundation Medicine, National Jewish Health, Weight Watchers, Bank of America/Merrill Lynch, American Family Insurance, Emblem Insurance, Volvo, Volkswagen, Honda, Lufthansa, Expedia, L'Oreal, Estee Lauder, Erno Laszlo, Victoria's Secret, RadioShack, Best Buy, CVS, Burger King, Domino's Pizza, Wendy's, Miller Coors, Brown Forman, Kahlua, Nike, Pearl Izumi.

CILVĒKJAUDA
#228 Sargi savu dzīvību ar zināšanām: onkologa padomi vēža diagnostikā - DR.ARVĪDS IRMEJS

CILVĒKJAUDA

Play Episode Listen Later May 15, 2025 74:36


Dr. Arvīds Irmejs šajā sarunā atklāj dzīvību glābjošus faktus par vēzi. Dakteris parāda, kā vēzis attīstās un kā tas kļūst arvien viltīgāks laika gaitā, tāpēc agrīnai diagnostikai un mamogrāfijas metodei ir izšķiroša nozīme, lai glābtu dzīvību un saglabātu dzīves kvalitāti. Pat neliela kavēšanās var dramatiski mazināt izveseļošanās iespējas. Dakteris arī norāda, kā 40% vēža gadījumu ir novēršami ar dzīvesveida izmaiņām.Dr. Arvīds Irmejs ir krūts ķirurģijas virsārsts PSKUS. Viņš ir RSU asociētais profesors, Onkoloģijas un molekulārās ģenētikas institūta direktors. Latvijas ārstu biedrības ceremonijā "Gada balva medicīnā" viņš saņēma balvu "Gada cilvēks medicīnā 2021".Šajā sarunā ārsts stāsta par mūsdienu ārstēšanas iespējām, pateicoties kam 80% sieviešu ar krūts vēzi vairs nav jāuztraucas par krūts zaudēšanu. Dakteris sniedz gan praktisku informāciju par skrīninga iespējām Latvijā, gan emocionālu atbalstu un cerību. Tā ir saruna, kas daudzas sievietes un viņu ģimenes var pasargāt no priekšlaicīgas nāves novēloti konstatēta vēža dēļ.Šīs intervijas saturs ir veidots sociālās kampaņas ietvaros, kas veltīta krūts veselībai. Kampaņa Latvijā tiek organizēta sadarbojoties ar krūts vēža pacientēm, pacientu organizācijām, vēža pacientu atbalsta organizāciju Onkoalianse, vadošajiem ārstiem ķīmijterapeitiem un farmācijas uzņēmumu Novartis.Sarunā pieminētos informācijas avotus un saites atradīsi 228. sarunas lapā.SARUNAS PIETURPUNKTI:00:00 - Agrīnā diagnostika glābj dzīvības00:02 – Iepazīšanās ar Dr. Arvīdu Irmeju00:04 - Krūts slimību centra darbība un komanda00:05 - Darba ikdiena un izmaiņas ārsta karjerā00:06 - Vīriešu krūts vēzis - retāk sastopams, bet tas pastāv00:08 - Ticības loma ārsta darbā, kas Dr. Irmejam dod spēku 00:10 - Pozitīva komunikācija ar pacientiem, kad svarīgi fokusēties uz risinājumiem, nevis sliktākajiem scenārijiem.00:14 - Svarīgi, lai pacients nebūtu viens, saņemot diagnozi.00:19 - Mūsdienu iespējas saglabāt krūti00:22 - Māņticības ietekme uz vēža ārstēšanu00:26 - Komplementārās medicīnas loma - fizisko aktivitāšu, uztura un garīgās veselības nozīme vēža ārstēšanas procesā.00:28 - Dzīvesveida ietekme uz vēža attīstību00:30 - Reproduktīvie faktori un krūts vēža risks00:32 - Garīgās veselības ietekme uz imunitāti un vēža attīstību.00:36 - Traģiskās kavēšanās sekas, kuras var mazināt00:40 - Vēža attīstības process un agrīnas diagnostikas nozīme00:44 - Krūts vēža statistika un jaunāku sieviešu risks, kas jāņem vērā00:45 - Mamogrāfijas pieejamība, valsts apmaksātais skrīnings sievietēm no 50 gadu vecuma un ieteikumi jaunākām sievietēm00:47 - Mamogrāfijas metodes drošības skaidrojums00:48 - Krūts vēža statistika Latvijā00:49 - Agrīna diagnostika var samazināt mirstību par trešdaļu00:51 – Skaidrojums, kādas ir mamogrāfijas priekšrocības pār citām metodēm00:54 - Godīga saruna par mamogrāfijas diskomfortu, kad ieguvumi no šī skrīninga atsver īslaicīgo diskomfortu.01:01 - Kā vīriešiem atbalstīt sievas, māsas, draudzenes krūts veselības pārbaudēs un ārstēšanas procesā01:03 - Pārmantotā vēža risks un ģenētiskās pārbaudes sievietēm01:06 – Interesanti pētījumi par krūšu palielināšanu un vēža risku01:07 - Nākotnes prognozes krūts vēža ārstēšanā, kad prevencija un veselīgs dzīvesveids ir efektīvākie risinājumi01:11 - Kā Dr. Irmejs saglabā līdzsvaru un atjaunojas01:14: Tava svarīgākā fotosesija

The Great Girlfriends Show
Beyond the Usual Aches- The Surprising Signs Your Body Might Be Battling Lupus

The Great Girlfriends Show

Play Episode Listen Later May 14, 2025 35:19


OncLive® On Air
S12 Ep50: Optimizing Today and Looking to Tomorrow in Metastatic CRPC - Homing in on EZH2

OncLive® On Air

Play Episode Listen Later May 14, 2025 43:33


This Oncology PER®Spectives™ podcast explores the role of EZH2 in metastatic castration-resistant prostate cancer (mCRPC) progression and its synergy with androgen receptor inhibitors. In this podcast, experts Neeraj Agarwal, MD, FASCO; Himisha Beltran, MD; and Maha Hussain, MD, FACP, FASCO, discuss the management of mCRPC. Acknowledgment of Educational Grant Support This activity is supported by an educational grant from Pfizer Inc. Accreditation/Credit Designation Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours. Instructions on How to Receive Credit Listen to this podcast in its entirety. Go to gotoper.com/credit and enter code: 6947 Answer the evaluation questions. Request credit using the drop-down menu. You may immediately download your certificate. Today's faculty are: Neeraj Agarwal, MD, FASCO Professor of Medicine Senior Director for Clinical Research HCI Presidential Endowed Chair of Cancer Research Director, Center of Investigational Therapeutics Director, Genitourinary Oncology Program Huntsman Cancer Institute, University of Utah (NCI-CCC) Salt Lake City, UT Disclosures: Grant/Research Support (paid to institution): Arvinas, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, GlaxoSmithKline, Immunomedics, Janssen, Lava, Merck, Nektar, Neoleukin, Novartis, Oric, Pfizer, Roche, Sanofi, Seagen, Takeda, Tra-con Himisha Beltran, MD Associate Professor of Medicine Director of Translational Research Within Medical Oncology Harvard Medical School Lank Center for Genitourinary Oncology and the Division of Molecular and Cellular Oncology Dana Farber Cancer Institute Boston, MA Disclosures: Grant/Research Support: Circle Pharma, Daiichi Sankyo, Novartis; Adviser: Amgen, AstraZeneca, Daiichi Sankyo, Novartis Maha Hussain, MD, FACP, FASCO Genevieve E. Teuton Professor of Medicine Professor, Medicine (Hematology/Oncology) Deputy Director Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine Chicago, IL Disclosures: Advisory Board: AstraZeneca, Bayer, Convergent Therapeutics, Honoraria: AstraZeneca, Bayer The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with ineligible companies. PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process. Off-Label Disclosure and Disclaimer This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity. Release Date May 14, 2025 Expiration Date May 14, 2026

Pharma and BioTech Daily
Pharma and Biotech Daily Podcast: Stay Informed on Drug Pricing, HIV Research, and Industry Updates

Pharma and BioTech Daily

Play Episode Listen Later May 13, 2025 2:09


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The White House has announced a new drug pricing policy that includes the revival of the most favored nations rule and extends to the private markets, leveraging the patent system, drug importation, and more. Meanwhile, Lilly's Zepbound has been found to have a superior benefit-risk ratio compared to Novo's Wegovy, BMS and Sanofi settle a Plavix lawsuit with Hawaii for $700 million, and biopharma companies are focusing on developing a cure for HIV as federal funding for related research is being cut. Sino Biological offers comprehensive solutions for autoimmune diseases, and Roche promises a $300 million investment in China production after a multibillion-dollar investment in the US. On the other hand, Lexeo and IGM have both announced significant layoffs. Novartis CEO has expressed concerns about Trump's pricing controls.Funding for HIV-related research and infrastructure is being cut by the Trump administration, leading biopharma companies like Gilead and Immunocore to focus on finding a cure for HIV. In the field of neurology, there is a need for more precise diagnostic tools to effectively treat neurodegenerative conditions. The new HHS vaccine requirement has been criticized by leading vaccine physician Paul Offit as potentially being anti-vaccine activism disguised as policy. Companies like Novartis, Bayer, and AstraZeneca are exploring new indications and innovations in radiopharmaceuticals, hoping to capitalize on a market that could reach $16 billion by 2033. The FDA has faced delays in reviewing certain drugs, while biotech stocks have fallen after the appointment of Vinay Prasad to succeed Marks at CBER. Vertex has decided to abandon AAV in the gene therapy space.Upcoming events include a webinar on surviving and thriving in the biotech downturn. Job opportunities in the biopharma industry include positions at Takeda, Daiichi Sankyo, and AbbVie. Heather McKenzie, senior editor at BioSpace, is open to suggestions for future coverage topics in neuroscience, oncology, cell & gene therapy, metabolic, or other areas.

AAD's Dialogues in Dermatology
Bonus: Diagnosis, Management, and Updates on Chronic Spontaneous Urticaria (Supported by Novartis)

AAD's Dialogues in Dermatology

Play Episode Listen Later May 12, 2025


Adam Friedman, MD, FAAD interviewed by Sabrina Shearer, MD, FAAD

Adpodcast
Albert Thompson - Managing Director, Digital Innovation - Walton Isaacson

Adpodcast

Play Episode Listen Later May 10, 2025 21:34


While carrying the “ethos” of a Marketing Technologist to many enterprises, He's always possessed a firm understanding of how technology has continued to transform the discipline of Marketing while disrupting today's conventional consumer engagement models. Over that past 20+ years his communications experience ranges from African American, Hispanic, LGBT, Asian American, Arab American, Indian, Boomers, Millennials, Urban, GM to International.He's been an audience "segmentation specialist" for clients looking to enhance their brand positioning by rethinking and redefining their Go-To-Market approach. Some of them include the likes of Lexus, NYPD, Medline, State Fair, Spalding, HBO, MCD, LA Sparks, Game Show Network, Verizon Wireless, Clear brand under Unilever, Ford Division, Lincoln Mercury, Burger King, Colgate, HSBC, Time Warner Cable, Home Depot, AstraZeneca, US Marines, Pfizer, Novartis, Merck, and Hyatt Resorts.His vantage point is oriented around enhancing a clients' Brand building efforts through ROI driven programs that leverage unique consumer insights and deliver relevant customer experience. I've always thought outside the traditional framework to solving business problems because the only thing constant is EVOLUTION. He has also done guest speaking for Meltwater Social, MediaPost, Digiday, ThinkLA, CYNOPSIS, Adweek, and The VAB inclusive of live and virtual events.  In the past, he's participated in guest speaker series for NYU, Baruch, University of Maryland, University of Nevada, and Georgetown.  Tune into the  HYPERLINK "https://protect-us.mimecast.com/s/IvUyCwp2q2H2LpTVv9A2?domain=open.spotify.com" The Transient Identiti, podcast which chronicles the Voice of the Consumer.Other than Strategic Intuition and the Human Truths in Marketing, "gratitude" is one thing he value deeply in business. Meaning, being grateful for how open-minded he's been to constantly challenge and even disrupt my own thinking!

The EMJ Podcast: Insights For Healthcare Professionals
AMJ Podcast | Episode 1: Harnessing Imaging Biomarkers in Asthma: Lessons from VESTIGE - Part 1/2

The EMJ Podcast: Insights For Healthcare Professionals

Play Episode Listen Later May 9, 2025 13:46


Join us for this two-episode mini-series featuring lead study authors, Mario Castro and Njira Lugogo, as they discuss key findings from the VESTIGE trial and their implications on asthma care.  Uncover: ·      The importance of patient phenotyping: How can biomarkers and imaging improve asthma management? ·      Mucus plugging and airflow obstruction: What does the latest research reveal? ·      Biologics and airway remodeling: What did the VESTIGE trial reveal about biologics and airway remodeling? ·      The role of imaging in clinical practice: How can CT scans provide new insights into asthma care? Speakers Mario Castro, University of Kansas School of Medicine, United States Njira Lugogo, University of Michigan, Ann Arbor, Michigan, United States Disclaimers: ·      This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ·      The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program ·      The content contained in this program was jointly developed by AMJ, the speakers, and Sanofi and Regeneron, and is not eligible for continuing medical education (CME) credits ·      See full US Prescribing Information for dupilumab ·      MAT-US-2412937 v2.0 - Pro1 Expiration Date: 04/21/2026 Speaker disclosures: ·      MC reports research support from the American Lung Association, AstraZeneca, Gala Therapeutics, Genentech, GSK, NIH, Novartis, PCORI, Pulmatrix, sanofi-aventis, Shionogi, and Theravance Biopharma, consultancy fees from Allakos, Amgen, Arrowhead Pharmaceuticals, Blueprint Medicines, Connect BioPharma, Genentech, GSK, Merck, Novartis, OM Pharma, Pfizer, Pioneering Medicines, sanofi-aventis, Teva, Third Rock Ventures, and Verona Pharmaceuticals, speaker fees from Amgen, AstraZeneca, Regeneron Pharmaceuticals Inc., and Sanofi, and royalties from Aer Therapeutics. ·      NLL reports research support paid to institution from Amgen, AstraZeneca, Avillion, Genentech, Gossamer Bio, GSK, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, consultancy fees from and participation on advisory boards with Amgen, AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, travel support from AstraZeneca, and honoraria for non-speaker bureau presentations from AstraZeneca and GSK. References: 1.        Castro M et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025;13:208-20. doi: 10.1016/S2213-2600(24)00362-X.

The EMJ Podcast: Insights For Healthcare Professionals
AMJ Podcast | Episode 1: Harnessing Imaging Biomarkers in Asthma: Lessons from VESTIGE - Part 2/2

The EMJ Podcast: Insights For Healthcare Professionals

Play Episode Listen Later May 9, 2025 20:08


Join us for this two-episode mini-series featuring lead study authors, Mario Castro and Njira Lugogo, as they discuss key findings from the VESTIGE trial and their implications on asthma care.  Uncover: ·      The importance of patient phenotyping: How can biomarkers and imaging improve asthma management? ·      Mucus plugging and airflow obstruction: What does the latest research reveal? ·      Biologics and airway remodeling: What did the VESTIGE trial reveal about biologics and airway remodeling? ·      The role of imaging in clinical practice: How can CT scans provide new insights into asthma care? Speakers Mario Castro, University of Kansas School of Medicine, United States Njira Lugogo, University of Michigan, Ann Arbor, Michigan, United States Disclaimers: ·      This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ·      The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program ·      The content contained in this program was jointly developed by AMJ, the speakers, and Sanofi and Regeneron, and is not eligible for continuing medical education (CME) credits ·      See full US Prescribing Information for dupilumab ·      MAT-US-2412937 v2.0 - Pro1 Expiration Date: 04/21/2026 Speaker disclosures: ·      MC reports research support from the American Lung Association, AstraZeneca, Gala Therapeutics, Genentech, GSK, NIH, Novartis, PCORI, Pulmatrix, sanofi-aventis, Shionogi, and Theravance Biopharma, consultancy fees from Allakos, Amgen, Arrowhead Pharmaceuticals, Blueprint Medicines, Connect BioPharma, Genentech, GSK, Merck, Novartis, OM Pharma, Pfizer, Pioneering Medicines, sanofi-aventis, Teva, Third Rock Ventures, and Verona Pharmaceuticals, speaker fees from Amgen, AstraZeneca, Regeneron Pharmaceuticals Inc., and Sanofi, and royalties from Aer Therapeutics. ·      NLL reports research support paid to institution from Amgen, AstraZeneca, Avillion, Genentech, Gossamer Bio, GSK, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, consultancy fees from and participation on advisory boards with Amgen, AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, travel support from AstraZeneca, and honoraria for non-speaker bureau presentations from AstraZeneca and GSK. References: 1.        Castro M et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025;13:208-20. doi: 10.1016/S2213-2600(24)00362-X.

Tagesgespräch
René Buholzer: Wie verhindern Sie Zölle auf Medikamente?

Tagesgespräch

Play Episode Listen Later May 8, 2025 25:52


Donald Trump erwägt, auch auf Medikamente Zölle zu erheben. Dies würde die Schweiz hart treffen, die Pharmabranche ist ein bedeutender Sektor der Wirtschaft. Wie will der Branchenverband Interpharma die USA davon abhalten? Der Chef von Interpharma ist zu Gast im Tagesgespräch. Die USA sind ein wichtiger Absatzmarkt für Schweizer Pharma-Firmen. Präsident Trump sieht die Versorgungssicherheit der USA in Gefahr, weil viele Medikamente importiert werden. Er droht darum, auch auf Medikamente Zölle zu erheben, damit die Produktion im Inland angekurbelt wird. Was würde das für die Schweiz bedeuten? Wie wollen sich die Schweizer Pharma-Firmen dagegen wehren? Und was heisst es für die Schweiz, wenn Novartis und Roche ihre Investitionen in die USA weiter ausbauen? Der Geschäftsführer von Interpharma, René Buholzer, spricht zum ersten Mal über die Position von Interpharma in dieser Frage, er ist zu Gast im Tagesgespräch.

ESC TV Today – Your Cardiovascular News
Season 3 - Ep.15 : Colchicine for secondary prevention - An algorithmic approach to the workup of syncope

ESC TV Today – Your Cardiovascular News

Play Episode Listen Later May 8, 2025 23:01


This episode covers: Cardiology This Week: A concise summary of recent studies Colchicine for secondary prevention An algorithmic approach to the workup of syncope Milestones: CIBIS II Host: Rick Grobbee Guests: Carlos Aguiar, Sanjit Jolly, Michele Brignole Want to watch that episode? Go to: https://esc365.escardio.org/event/1805 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Michele Brignole, Diederick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Sanjit Jolly has declared to have potential conflicts of interest to report: grant support from Boston Scientific, honorarium from Boston Scientific, Shockwave, Abiomed, SIS, and Teleflex.  Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

ESC TV Today – Your Cardiovascular News
Season 3 - Ep.15 : Extended interview on An algorithmic approach to the workup of syncope

ESC TV Today – Your Cardiovascular News

Play Episode Listen Later May 8, 2025 9:02


Host: Rick Grobbee Guest: Michele Brignole Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1805?r  Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Michele Brignole, Diederick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Pharma and BioTech Daily
Pharma and Biotech Daily: The Latest in Industry News and Insights

Pharma and BioTech Daily

Play Episode Listen Later May 8, 2025 1:57


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novo Nordisk predicts a brighter future for Wegovy with the end of the semaglutide shortage, but analysts remain skeptical as Eli Lilly's Zepbound gains ground in sales. The new HHS vaccine requirement has raised questions about its true intentions, with leading vaccine physician Paul Offit criticizing the lack of clarity. Meanwhile, pharmaceutical imports from Ireland are on the rise, biotech stocks fell after Vinay Prasad was named to succeed Marks at CBER, and Lotte Biologics' ADC facility in Syracuse offers end-to-end services for antibody manufacturing. CRISPR's Casgevy is gaining traction with more gene therapy proof of concept expected in 2025, impacting M&A and IPOs in the biotech industry. Summit Pharmaceuticals is nearing the first global phase III data for Keytruda, set to lose exclusivity in 2028 and potentially face competition from biosimilars. A report suggests that low-price drug nations are benefiting from US innovation, undervaluing innovative medicines by 90%. VC financing in biopharma declined by 20% in Q1, but megarounds kept the median deal size high. M&A and IPOs faced challenges due to policy issues, leading to an increase in licensing deals. Novo vows to improve market access for Wegovy, while Trump orders FDA to ease US plant expansion and increase inspections of foreign facilities. BMS pledges a $40 billion investment in the US, Novartis makes M&A moves, and Lilly remains unfazed by CVS's decision to side with Novo in the obesity market battle. Some drugmakers are stockpiling products in the US amid Trump's trade war. NGM terminates half of its staff as its lead asset moves through a registrational study. Job opportunities in clinical quality assurance audit, RBQM central statistical monitoring, and field medical capabilities are available.

TrainSmart: The Medical Device Educators’ Podcast
158 | From Protocol to Practice: An Interview with Liana Mari-Gordon

TrainSmart: The Medical Device Educators’ Podcast

Play Episode Listen Later May 6, 2025 16:59


In this episode, Liz Cumby is joined by Liana Mari-Gordon, an expert in mechanical engineering and surgical training, to discuss best practices throughout the clinical trial phase of medical devices. Liana shares her experiences of learning how what "looks good on paper" may need to be updated when the device is in the hands of a physician. They delve into the importance of standardizing training, capturing and sharing field data, and maintaining honest conversations about challenges and successes. The episode also highlights methods to implement continuous improvements and ensure best practices are disseminated across users.In 2025, we're embarking on a MedDevice Training Journey: From clinical trials to standard of care. Join us all year long as we explore training at each stage of the product life cycle.Need help developing your clinical trial training strategies? Contact us at training@cumbyconsulting.com.Related Resources:Liana Mari-Gordon is the owner of Liana Mari Gordon Consulting LLC, providing project management, training operations, and device development services to help set teams up for successful execution of training programs. She has spent her career in the medical device and pharmaceutical industries ranging from small startups to Fortune 500 companies. As a mechanical engineer designing spinal implants and surgical instruments at Globus Medical, her experience conducting hands-on training, supporting surgical cases, and evaluating product complaints from the field formed her passion for informed use of product and positive user experience. She joined Orbit Biomedical, an ophthalmic medical device startup, and became a surgical technical expert responsible for clinical trial device and procedure training. Liana's responsibilities expanded to managing the logistics and execution of training programs and surgery support for a global team and multiple clinical trials as the startup merged with Gyroscope Therapeutics. As training operations lead, Liana led communication between cross functional teams to ensure readiness of and consistency across internal team members and trial sites. When acquired by Novartis, Liana was a key member in integrating existing practices within the larger organization and facilitating process improvements when needed. Liana earned a BS and MEng in mechanical engineering from Cornell University.Subscribe to our newsletter to hear more about the journey from clinical trials to standard of care! Click here to subscribe!Connect with us on LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠Liana Mari-Gordon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Cumby Consulting⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Rachel Medeiros⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Liz Cumby⁠⁠⁠⁠⁠About Cumby Consulting: Cumby Consulting's team of professionals deliver innovative MedTech training services for physicians, sales representatives, teaching faculty, key opinion leaders and clinical development teams. Whether you need a complete training system developed to deliver revenue sooner or a discrete training program for a specific meeting, Cumby Consulting will deliver highly strategic, efficient programs with uncompromising standards of quality.

Knowledge Cast by Enterprise Knowledge
Barry Byrne - Global Head of Knowledge Management at Novartis & Organizer for Knowledge Summit Dublin

Knowledge Cast by Enterprise Knowledge

Play Episode Listen Later May 6, 2025 45:31


Enterprise Knowledge CEO Zach Wahl again speaks with Barry Byrne, Global Head of Knowledge Management at Novartis and founder and organizer of the Knowledge Summit Dublin conference.In this conversation, Zach and Barry discuss Barry's growing knowledge management team at Novartis, how to measure KM success, and best practices for conducting (and scaling!) knowledge capture before valuable team members leave an organization. They also share what they're most excited about at Knowledge Summit Dublin this year, especially the "salmon of knowledge." For more information on Knowledge Summit Dublin, check it out at ⁠https://www.knowledgesummitdublin.com/⁠.Click ⁠here⁠ to listen to Barry's first Knowledge Cast episode.To learn more about Enterprise Knowledge, visit us at: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠enterprise-knowledge.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.EK's Knowledge Base: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://enterprise-knowledge.com/knowledge-base/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Contact Us: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://enterprise-knowledge.com/contact-us/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/enterprise-knowledge-llc/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter/X: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/ekconsulting⁠⁠⁠

Pharma and BioTech Daily
Pharma and Biotech Daily: Navigating Tariffs, M&A Trends, and Industry Challenges

Pharma and BioTech Daily

Play Episode Listen Later May 1, 2025 1:52


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novartis recently acquired Regulus for $1.7 billion, signaling a trend of increased M&A activity in the pharmaceutical industry. Many companies have hinted at upcoming deals during recent earnings calls, which is seen as a positive sign for the biopharma ecosystem amidst challenges like tariffs and potential drug pricing pressures. GSK remains optimistic about M&A opportunities despite the threat of tariffs, with CEO Emma Walmsley emphasizing a cautious and disciplined approach to dealmaking. Trilink Biotechnologies has introduced custom sets of mRNA for screening studies, offering flexibility and scalability for research needs. The AACR 2025 conference featured promising data from Marengo and Briacell, while Pfizer CEO Albert Bourla has been lobbying against pharmaceutical industry tariffs proposed by President Trump. Overall, the industry is seeing a mix of challenges and opportunities, with companies navigating trade tensions and economic uncertainties while also pursuing strategic growth through acquisitions and innovative research initiatives.Pharmaceutical companies are navigating political uncertainties, particularly in relation to tariffs and dealmaking with China. Major companies are investing billions in US manufacturing to avoid tariffs threatened by President Trump. Despite lobbying efforts, Trump has expressed national security concerns regarding the pharmaceutical industry. CEO-to-employee pay gaps in the industry remain significant. Novartis, GSK, and AstraZeneca are facing challenges and making strategic shifts in response to political and market conditions. Tariff uncertainty is impacting Q1 earnings, with companies like Merck taking significant financial hits. Despite these challenges, the industry remains active with mergers and acquisitions. Upcoming events and job opportunities in the biopharma sector are highlighted.

Info 3
Roche, Novartis und ihre Milliardeninvestitionen in den USA

Info 3

Play Episode Listen Later May 1, 2025 13:45


Die Ankündigungen von Roche und Novartis, Milliarden in den USA zu investieren, sorgten jüngst für Aufsehen und lösten hierzulande Sorgen über eine Standortschwächung aus. Sind die Summen womöglich als Abwendung von Europa zu verstehen? Weitere Themen: In der Schweiz erfreut sich das Homeoffice auch nach den Pademiejahren noch grosser Beliebtheit. Das zeigt der Blick auf Stellenportale im Internet: Die Zahl der Stellen, die zumindest teilweise Arbeit im Homeoffice anbieten, nimmt weiter zu. Im April 1955 wurde in den USA die Impfung gegen Kinderlähmung zugelassen. Seither hat die Krankheit zwar ihren Schrecken verloren, aber es gibt sie noch. Jüngst gab es in New York einen Erkrankungsfall und in Afghanistan und Pakistan ist Polio endemisch. Droht auch hierzulande eine Rückkehr der Krankheit?

echtgeld.tv - Geldanlage, Börse, Altersvorsorge, Aktien, Fonds, ETF
egtv #402 Schweizer Aktien-Comeback! Nestlé, Novartis, Roche & Jungfraubahn im Check |

echtgeld.tv - Geldanlage, Börse, Altersvorsorge, Aktien, Fonds, ETF

Play Episode Listen Later May 1, 2025 74:40


Pharma and BioTech Daily
Pharma and Biotech Daily: AstraZeneca's Shift, FDA Concerns, Novartis CEO Speaks Out, Pfizer's Savings, and More

Pharma and BioTech Daily

Play Episode Listen Later Apr 30, 2025 1:07


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. AstraZeneca has decided to abandon its neuroscience research and focus on weight loss and immunology, following recent discontinuations in Alzheimer's and migraine research. FDA experts are urging Commissioner Makary to resist politicization of the agency. Novartis CEO dismisses tariffs but warns against Trump's pricing controls. Pfizer announces $1.7 billion in cost savings, including a revamp of its R&D organization. Trilink Biotechnologies introduces custom sets of mRNA for screening studies. Other news includes Steminent showcasing therapy for spinocerebellar ataxia, Regeneron's shares tumbling, and ABEONA receiving FDA approval for a gene therapy for a rare skin disease. In summary, AstraZeneca shifts focus, FDA concerns arise, Novartis CEO speaks out, Pfizer announces cost savings, Trilink Biotechnologies introduces new product, Steminent showcases therapy, Regeneron's shares tumble, and ABEONA receives FDA approval.

CNBC’s “Money Movers”
Deutsche Bank Cuts its S&P Target…Amazon in the political crosshairs…Novartis' CEO talks tariffs 4/29/25

CNBC’s “Money Movers”

Play Episode Listen Later Apr 29, 2025 41:55


Despite the rally we've seen in the past few days, Deutsche Bank cuts its S&P 500 and S&P earnings target due to concerns about tariffs. We speak to the firms Chief U.S. equity strategist. Plus, Amazon gets caught in the political crosshairs ahead of earnings later this week. We breakdown the drama and how to position. And, Novartis reports a strong beat and says it can manage any tariffs that come ahead. We speak with the CEO. 

Ransquawk Rundown, Daily Podcast
Europe Market Open: European futures green after strong bank earnings and auto tariff reports; Canada's Carney wins election

Ransquawk Rundown, Daily Podcast

Play Episode Listen Later Apr 29, 2025 3:29


US President Trump is expected to soften the impact of his automotive tariffs, according to WSJ citing sources.Canada's ruling Liberals, led by Mark Carney, won the national election but will need to form a minority government.APAC stocks were mostly in the green but with gains capped following the choppy performance stateside.European equity futures indicate a slightly positive open with Euro Stoxx 50 future up 0.1% after the cash market finished with gains of 0.3% on Monday.DXY is attempting to claw back some of yesterday's losses, EUR/USD has slipped back onto a 1.13 handle, USD/JPY bounced from support at 142.Looking ahead, highlights include German GfK Consumer Sentiment, Spanish GDP, HICP, EZ Business Sentiment, US Advance Goods Trade, JOLTS Job Openings, ECB's Cipollone, BoE's Ramsden, SNB's Martin & US Treasury Secretary Bessent, Supply from UK & Italy.Earnings from Starbucks, Visa, Snap, PPG, SoFi, PayPal, JetBlue, Coca-Cola, UPS, Pfizer, Royal Caribbean, Spotify, HSBC, BP, AstraZeneca, Ocado, Entain Lufthansa, Porsche AG, Deutsche Bank, Capgemini, Amundi, Rexel, Scor, URW, Carlsberg, Novartis, Logitech & BBVA.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

The John Batchelor Show
Good evening: The show begins in Switzerland where a decision is made to build Roche and Novartis plants in the US...

The John Batchelor Show

Play Episode Listen Later Apr 23, 2025 8:31


Good evening: The show begins in Switzerland where a decision is made to build Roche and Novartis plants in the US... 1927 SWITZERLAND This appears to be an email from John Batchelor detailing the schedule for a CBS Eye on the World radio/podcast show. Here's a brief summary of the program segments: First Hour: 9:00-9:15: Markets - Switzerland Pharma and US Manufacturing (Liz Peek) 9:15-9:30: Markets - Biden in Disorder (Liz Peek) 9:30-9:45: Lebanon - Hezbollah Weapons (David Daoud, Bill Roggio) 9:45-10:00: Iran - Discussed as "Defeated in All Directions" (David Daoud, Bill Roggio) Second Hour: 10:00-10:15: Trade and Congress history (Philip Wallach, AEI/Civitas Institute) 10:15-10:30: Continued Trade and Congress discussion 10:30-10:45: Russia and Oil Prices (Ekaterina Zolotova) 10:45-11:00: China and Deepseek Deceptions (Jack Burnham) Third Hour: 11:00-11:15: London Calling - Blaming Japan, Germany, China (Joseph Sternberg) 11:15-11:30: London Calling - Rachel Reeves in Washington 11:30-11:45: Antisemitism at Harvard (Peter Berkowitz) 11:45-12:00: Progressivism at Harvard (Peter Berkowitz) Fourth Hour: 12:00-12:15: Iran Nuclear Weapons (John Bolton) 12:15-12:30: USAF Kinetic Warfare in CENTCOM (General Blaine Holt) 12:30-12:45 & 12:45-1:00: Soviet Kompromat and Trump in the 1980s (Craig Unger) Would you like me to elaborate on any of these segments or topics?

Made IT
Il futuro dell'energia passa dal nucleare? La visione di Stefano Buono, Founder & CEO newcleo (2024)

Made IT

Play Episode Listen Later Apr 21, 2025 49:18


L'episodio di oggi racconta la straordinaria storia di un fisico nucleare e imprenditore di fama internazionale. Parliamo di Stefano Buono, co-founder e CEO di newcleo.Fondata nel 2021 insieme a Luciano Cinotti ed Elisabeth Rizzotti, newcleo sviluppa reattori nucleari di ultima generazione destinati a produrre energia pulita, sicura e sostenibile. In modo del tutto innovativo, i reattori di newcleo utilizzeranno le scorie nucleari come combustibile eliminando la complessità dello smaltimento dei rifiuti derivanti dall'energia nucleare. In un solo anno newcleo ha raccolto 400 milioni di euro con round partecipati anche da Exor, Liftt e Club degli investitori, e nel 2023 ha lanciato un aumento di capitale da 1 miliardo di euro.Ma questa non è la prima esperienza imprenditoriale di Stefano, nel 2002 Stefano fonda con Paolo Pomè l'Advanced Accelerator Applications per commercializzare un brevetto sviluppato durante gli anni al CERN insieme a Carlo Rubbia e sviluppare prodotti di medicina nucleare per la diagnostica PET e SPECT e la terapia oncologica. Nel 2017 viene registrato il Lutathera, un medicinale per la cura dei tumori dell'intestino, dando inizio alla crescita esponenziale del mercato dei prodotti radiofarmaceutici. Advanced Accelerator Applications è stata quotata al Nasdaq e poi venduta a Novartis per 3.9 miliardi di dollari ma la crescita è ancora strabiliante, contando 1100 dipendenti, sedi in 11 paesi e una rete di distribuzione in 30 paesi.La passione per la scienza e lo spirito imprenditoriale sono sempre stati centrali nella vita di Stefano.Ascoltando Stefano capirete infatti che ha l'ambizione di un imprenditore ma l'anima di uno scienziato interessato ad impatto e risultati. E' una persona super privata non interessata a esaltare il suo successo, quindi siamo particolarmente lusingate ci abbia dedicato un po' del suo tempo prezioso. Con Stefano abbiamo parlato della sua vita da innovatore e dell'importanza del nucleare per produrre un'energia più pulita, indipendente e sostenibile. Speriamo che la chiacchierata possa essere utile per approfondire una tematica così attuale, importante e a volte controversa.SPONSORClemi's Market è il brand di healthy food che ho lanciato con mia sorella e ho una bellissima notizia da annunciarvi, da oggi potete trovare due gusti delle nostre barrette energetiche in 95 Esselunga in giro per l'Italia e presto anche su Esselunga.com ! Potete trovare la lista esatta dei negozi qui: https://www.clemismarket.com/pages/store-locatorSe state cercando uno snack sano ma allo stesso gustoso con un etichetta pulitissima di soli 5 ingredienti naturali, provatele e fatemi sapere cosa ne pensate.

Ask Dr. Drew
Sasha Latypova: Covid “Military-Intelligence Operation” Dossier Alleges DOD Links To Pandemic Outbreak – Ask Dr. Drew – Ep 477

Ask Dr. Drew

Play Episode Listen Later Apr 19, 2025 78:40


“Covid was not a public health event, although it was presented as such to the world's population,” writes ex-pharma executive Sasha Latypova in The Covid Dossier coauthored by Debbie Lerman. “It was a global operation, coordinated through public-private intelligence and military alliances and invoking laws designed for CBRN (chemical, biological, radiological, nuclear) weapons attacks.” Sasha Latypova is a retired pharmaceutical R&D executive with 25 years of experience, having managed contract research organizations for over 60 companies, including Pfizer and Novartis. She specialized in cardiovascular safety assessments, collaborating with the FDA. More at https://x.com/sasha_latypova and https://sashalatypova.substack.com Connie Shields advocates for ostrich farmers and resists government overreach in Canada. More at https://unlockalberta.substack.com Gwen Lynn is an environmental safety scientist and host of In A Green Minute. With a BS and MS in Environmental Science, she manages health and safety for construction and film industries, specializing in sustainability. She hosted Outdoor Wild Kids Adventures. More at https://inagreenminute.com 「 SUPPORT OUR SPONSORS 」 Find out more about the brands that make this show possible and get special discounts on Dr. Drew's favorite products at https://drdrew.com/sponsors  • HEART FACTORS PLUS - A powerful formula packed with L-arginine, a key amino acid that's been shown to enhance nitric oxide physiology and could play a key role in supporting healthy blood flow and circulation. Get a FREE bottle with your order at https://heartfactorsplus.com/drew • ACTIVE SKIN REPAIR - Repair skin faster with more of the molecule your body creates naturally! Hypochlorous (HOCl) is produced by white blood cells to support healing – and no sting. Get 20% off at https://drdrew.com/skinrepair • FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at https://drdrew.com/fatty15 • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at https://drdrew.com/paleovalley • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at https://twc.health/drew 「 MEDICAL NOTE 」 Portions of this program may examine countervailing views on important medical issues. Always consult your physician before making any decisions about your health. 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (https://kalebnation.com) and Susan Pinsky (https://twitter.com/firstladyoflove). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Learn more about your ad choices. Visit megaphone.fm/adchoices

The CEO Sessions
Line in the Sand - COO Wedgewood, Stan Howell

The CEO Sessions

Play Episode Listen Later Apr 10, 2025 39:43 Transcription Available


Where do you draw the line as a leader?Stan Howell, a pharmaceutical powerhouse with 25+ years at giants like Johnson & Johnson, Merck, and Novartis, shares a powerful message.He's now risen to the corner office as COO at Wedgewood holding true to his personal values and guiding principles.Wedgewood is the largest US veterinary compounding pharmacy, serving over 70,000 vets and one million animals yearly. He didn't have some grand plan; he chose to seize the opportunities and learned along the way. Stan's journey from a packaging line to leading global operations is packed with unexpected turns and powerful lessons in leadership, discipline, and the criticality of passion. Learn how he navigated massive industry shifts and why he believes authentic communication is the only communication that truly resonates. You'll also Discover-A Surprising Key to Accelerating Your Career -Why Motivation is Overrated in Leadership -An Unexpected Downside of Becoming Indispensable -How to Craft a Communication Strategy That Works -A Simple 3-Word Blueprint for True Leadership -----What are your non-negotiable principles in your career?-----Follow Stan on LinkedIn here: https://www.linkedin.com/in/stan-howell/Learn more about Wedgewood: https://www.wedgewood.com/-----Connect with the Host, #1 bestselling author Ben FanningSpeaking and Training inquiresSubscribe to my Youtube channelLinkedInInstagramTwitter

Do Good To Lead Well with Craig Dowden
Reconstructing Inclusion: Building Sustainable and Inclusive Organizations with Amri Johnson

Do Good To Lead Well with Craig Dowden

Play Episode Listen Later Apr 3, 2025 56:17


Discover how to revolutionize your organization by embedding inclusion into its very DNA. Explore the foundations of Amri's groundbreaking book, "Reconstructing Inclusion," which challenges the norms of traditional DEI approaches. Through his experiences at Novartis, Amri shares how organizations can cultivate environments where everyone thrives by aligning skills and capabilities with their purpose.Addressing the elephant in the room, we tackle the current backlash against DEI efforts and explore the concept of anti-fragility. Learn how creating spaces for civil dialogue and fostering cognitive diversity can combat ideological resistance and enhance productivity. Amri also highlights how focusing on agency and prevention versus (over)reaction leads to a more sustainable and inclusive organizational culture.We close the conversation unpacking the nuances of cultural intelligence and relational fitness, vital tools for navigating the complexities of building inclusive environments for all. Join us for this transformative conversation where you will walk away with actionable strategies to foster growth, collaboration, and inclusivity in your organization.What You'll Learn- How to build sustainable and inclusive organizations.- A challenge to traditional DEI frameworks.- An introduction to the COST model—Care, Openness, Safety, and Trust.- Ways to create vibrant, thriving work environments that inspire and empower everyone.Podcast Timestamps(00:00) - Creating Inclusive and Generative Organizations(10:27) - Navigating DEI Backlash and Anti-Fragility(23:02) - Creating Inclusive Organizations(28:20) - Embracing Inclusion Beyond Surface Identities(41:51) - Navigating Cultural Intelligence for Inclusion(47:46) - Sustainable Inclusion Practices in OrganizationsKEYWORDSPositive Leadership, Inclusive Organizations, Social Capitalism, Inclusion Strategy, DEI Frameworks, Sustainable Practices, Anti-Fragility, Cognitive Diversity, Respectful Dialogue, Cultural Intelligence, Relational Fitness, Inclusive Leadership, Collaborative Growth, Mutual Understanding, CEO Success